Advance your ADC research with precision biomarkers & spatial intelligence
OmniVUE™ accelerates ADC therapeutic development by providing high-fidelity, quantitative biomarker detection (>90% concordance with pathology gold standard) and pathology-grade precision
DAB Assay
InSituPlex® Assay
HER2 Detection with InSituPlex® assay is concordant with the current Pathology Gold Standard, DAB
Broad dynamic range of detection
Accurate classification and quantitative detection of varying biomarker levels (e.g., HER2 – 0, 1+ and 2+)
Enhanced spatial immunoprofiling
Identify advanced spatial phenotypes through co-detection of multiple biomarkers in one assay with complete panel flexibility
Pathology-grade precision
Pathology-grade biomarker detection with coefficients of variation significantly less than 20% across independent runs
Accelerated timelines
Reduced custom biomarker panel development timelines from 6+ months to just 6-8 weeks, due to simplicity and modularity of InSituPlex® assays
Powerful spatial analysis
Deep spatial insights via Al-enhanced spatial image data science, capable of analyzing 100s of samples within the same day on the cloud
Customizable OmniVUE™ panels built from a validated menu of 30+ biomarkers, including TROP2, HER2, TF, and FR
20 more ADC biomarkers available soon!
See More
Higher quality multiplex data
Orders of magnitude greater signal| amplification; signal-to-noise ratio of up to 30:1
See Faster
Accelerated, flexible data creation
Build, deploy and iterate panels 3x faster, saving months – year(s) of time
See In Situ
More robust, Al-driven insights
Deeper insights from state-of-the-art, Al-enabled spatial image analysis
OmniVUE™ panels enable researchers to visualize and quantify the complex spatial relationships between tumor cells, immune cells, and therapeutic targets, providing critical insights for ADC development.
